Marinus Pharma (MRNS) Highlights Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. DPZ
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to Marinus Pharma (MRNS) Highlights Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus

Marinus Pharma (MRNS) Prices 28M Share Common Offering at $1.25/Sh; Announces Concurrent Private Placement

December 11, 2019 9:15 AM EST

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced the pricing of an underwritten public offering of 28,000,000 shares of common stock at a public offering price of $1.25 per share. The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters... More